Company Filing History:
Years Active: 2020-2024
Title: Innovations by Cynthia Chang in Next Generation Sequencing
Introduction
Cynthia Chang is a notable inventor based in San Mateo, CA. She has made significant contributions to the field of biotechnology, particularly in the area of next generation sequencing (NGS). With a total of 2 patents, her work has advanced the methodologies used in genetic research and analysis.
Latest Patents
Cynthia's latest patents focus on methods for preparing a next generation sequencing (NGS) library from a ribonucleic acid (RNA) sample. These methods involve combining the RNA sample with a first strand cDNA primer and a template switch oligonucleotide under specific synthesis conditions. One of the key aspects of her invention includes the use of a first post-tagmentation amplification primer binding domain. The resultant product undergoes amplification to produce double stranded cDNA, which is then tagmented with a transposome that includes a second post-tagmentation amplification primer binding domain. The tagmented sample is subjected to further amplification using primers that include sequencing platform adapter constructs, ultimately producing a comprehensive NGS library. Additionally, her patents encompass compositions and kits that facilitate the application of these methods.
Career Highlights
Cynthia Chang is currently employed at Takara Bio USA, Inc., where she continues to innovate in the field of genetic sequencing. Her work has been instrumental in enhancing the efficiency and accuracy of NGS technologies, which are crucial for various applications in genomics and molecular biology.
Collaborations
Cynthia collaborates with her coworker, Magnolia Bostick, who also contributes to the advancements in their shared field. Their teamwork exemplifies the collaborative spirit that drives innovation in biotechnology.
Conclusion
Cynthia Chang's contributions to next generation sequencing represent a significant advancement in genetic research methodologies. Her innovative patents and ongoing work at Takara Bio USA, Inc. continue to shape the future of biotechnology.